Something new is coming into focus. 👀 A fresh look. A new chapter. The same commitment to connecting science with everyday practice. Stay tuned. The reveal is coming soon. 🔜 #ComingSoon #Oncology

🩺 Practice Update: The @NCCN guidelines have incorporated cosibelimab (Unloxcyt) for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. Read more: targetedonc.com/view/nccn-co… #CSCC #SkinCancer #Oncology #CancerCare

Morana Vojnic, MD, MBA (@RutgersCancer) discussed how FET-PET imaging, advanced molecular testing, and personalized treatment approaches are shaping the future of brain tumor care. 💬 Full interview: targetedonc.com/view/vojnic-… #NeuroOncology #PrecisionMedicine | @Moranaaa

🔬 A new analysis reveals major gaps in US #TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities. Read more: targetedonc.com/view/triple-… #RuralHealth #CancerCare #ClinicalTrials #BreastCancer

Alicia Morgans, MD, MPH (@DanaFarber) discusses findings from ARAAT, a real-world analysis comparing darolutamide vs abiraterone when each is added to an ADT and docetaxel backbone in #mHSPC. 🎥 WATCH: targetedonc.com/view/dr-alic… #Oncology #ProstateCancer #RWD | @CaPsurvivorship

🔬 The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with #PolycythemiaVera receiving standard-of-care therapy. Read more: targetedonc.com/view/rusfert… #Hematology #ClinicalResearch

🔎 FDA News: MC001, an investigational chemoimmunotherapy ADC, has received #FDA fast track designation for #PancreaticCancer. Read more: targetedonc.com/view/mc001-r… #Oncology #CancerTreatment #GIOncology

🔬 Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell #RCC, alone and in key first-line combinations. Read more: targetedonc.com/view/casdati… #ccRCC #KidneyCancer #GUOncology #Oncology

📊 According to a new analysis, rural #BreastCancer deaths are rising faster than urban rates, driven by low income, later diagnosis, and treatment gaps. Read more: targetedonc.com/view/rural-u… #CancerCare #HealthDisparities #PublicHealth #Epidemiology

🔬 The TASKIN trial found a 12-month OS rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors. Read more: targetedonc.com/view/vilamak… #ColorectalCancer #CRC #GIOncology #Oncology

What does taletrectinib’s sNDA approval change for patients with ROS1-positive non–small cell lung cancer? On this episode of Targeted Talks, Lyudmila Bazhenova, MD, breaks down the long-term efficacy data. targetedonc.com/viewbazhenov…

🔬 SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery. Read more: targetedonc.com/view/neoadju… #Oncology #RCC #KidneyCancer #GUOncology

📢 BREAKING: The #FDA has approved dostarlimab for MSI-H/dMMR locally advanced #RectalCancer, helping many patients avoid surgery, radiation, and chemo. Read more: targetedonc.com/view/dostarl… #GIOncology #FDANews #Oncology #CancerTreatment #CancerCare

🔬 In patients 45+ with papillary #ThyroidCancer, men with dual BRAF V600E and TERT promoter mutations face sharply higher mortality, reshaping risk stratification. Read more: targetedonc.com/view/papilla… #PTC #Oncology #CancerCare #CancerResearch

🔬 Selpercatinib achieved a 53% ORR in pediatric patients with RET-altered solid tumors, with no treatment discontinuations due to treatment-related AEs in LIBRETTO-121. Read more: targetedonc.com/view/selperc… #Oncology #CancerTreatment #CancerResearch #CancerCare

🩺 In a Case-Based Roundtable event, experts debate second-line tivozanib for advanced #RCC, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit. Read more: targetedonc.com/view/conside… #KidneyCancer #Oncology #GUOncology

J. Thaddeus Beck, MD (@HOGONC) discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences. 💬 Full interview: targetedonc.com/view/subcuta… #Oncology #DrugDelivery #CancerCare

During a live event, Seth M. Pollack, MD (@LurieCancer) and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor. 💬 Follow the conversation: targetedonc.com/view/new-tgc… #TGCT #Oncology #ClinicalPractice #CaseBasedRoundtable

🔎 FDA News: The #FDA has granted a second fast track designation to invikafusp alfa for unresectable, locally advanced or metastatic TMB-H solid tumors that have progressed following prior treatment. Read more: targetedonc.com/view/invikaf… #Oncology #CancerTreatment

🔬 Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias. Read more: targetedonc.com/view/iopofos… #Lymphoma #Hematology #Oncology #Waldenstrom